Physician profile
James M Long
NPI 1194821868
$897.89
in general payments reported to CMS, 2019-2025
11 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.78 · 2021: $44.60 · 2022: $31.80 · 2023: $254 · 2024: $134 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.91 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $181.51 | 2023-2025 | |
| Array Biopharma INC | $107.06 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Merck Sharp & Dohme LLC | $93.72 | 2023-2025 | Keytruda, Lynparza |
| Celgene Corporation | $92.10 | 2025 | Reblozyl |
| Abbvie INC. | $75.38 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.59 | 2019-2024 | Iclusig |
| Deciphera Pharmaceuticals INC. | $35.48 | 2025 | Romvimza, Qinlock |
| Beigene USA, INC. | $29.88 | 2025 | Tevimbra |
| Lilly USA, LLC | $23.89 | 2023 | Verzenio |
| Janssen Biotech, INC. | $14.62 | 2023 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.